The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 602-611

  Zhang, Li ^a,b   Ren, Xingcong ^b   Cheng, Yan ^b   Liu, Xiuping ^c   Allen, Joshua E ^b   Zhang, Yi ^a   Yuan, Yunsheng ^b   Huang, Siu Yuan ^b   Yang, Weiwei ^c   Berg, Arthur ^b   Webb, Becky S ^b   Connor, James ^b   Liu, Chang Gong ^c   Lu, Zhimin ^c   El Deiry, Wafik S ^b   Yang, Jin Ming ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain tumor; Differentiation; Glioma stem cells; NF B inhibitor; SN50

Indexed keywords

SN 50; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROGENY; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; TUMOR INVASION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL DIFFERENTIATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NF-KAPPA B; PEPTIDES; TUMOR CELLS, CULTURED;

EID: 84899860144     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28158     Document Type: Article

References (24)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
2. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13:69-80; PMID:18167341; http://dx.doi.org/10.1016/j.ccr.2007.12.005 (Pubitemid 350309742)
3. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16:2443-9; PMID:20371685; http://dx.doi.org/10.1158/1078-0432.CCR-09-3106
4. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10:717-28; PMID:22704512; http://dx.doi.org/10.1016/j.stem.2012.05.007
5. Akhtar K, Bussen W, Scott SP. Cancer stem cells - from initiation to elimination, how far have we reached? (Review). [Review]. Int J Oncol 2009; 34:1491-503; PMID:19424566
6. Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev 2011; 25:75-81; PMID:21216511; http://dx.doi.org/10.1016/j.blre.2010.11.001
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236 (Pubitemid 44949604)
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas. 0530291100 (Pubitemid 36418143)
9. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353:811-22; PMID:16120861; http://dx.doi.org/10. 1056/NEJMra043666
10. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010; 80:654-65; PMID:20457135; http://dx.doi.org/10.1016/j.bcp.2010.04.035
11. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761-5; PMID:17151667; http://dx.doi.org/10.1038/nature05349 (Pubitemid 44949605)
12. Chan XH, Nama S, Gopal F, Rizk P, Ramasamy S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep 2012; 2:591-602; PMID:22921398; http://dx.doi.org/10.1016/j.celrep.2012.07.012
13. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res 2004; 64:7011-21; PMID:15466194; http://dx.doi.org/10.1158/0008-5472.CAN-04-1364 (Pubitemid 39331011)
14. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7:489-97; PMID:19372578; http://dx.doi.org/10.1158/1541-7786.MCR-08-0360
15. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 2013; 288:26167-76; PMID:23902772; http://dx.doi.org/10.1074/jbc.M113.477950
16. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120:41-50; PMID:20051635; http://dx.doi.org/10.1172/JCI41004
17. Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 2011; 71:5569-78; PMID:21730024; http://dx.doi.org/10.1158/0008-5472. CAN-10-2805
18. Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011; 129:2720-31; PMID:21384342; http://dx.doi.org/10.1002/ijc. 25975
19. Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010; 12:1205-19; PMID:20861085
20. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18:19-26; PMID:18440219; http://dx.doi.org/10.1016/j.gde.2008.01.020
21. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12:86; PMID:23915189; http://dx.doi.org/10.1186/1476-4598-12-86
22. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2011; 2:646-53; PMID:21896960
23. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270:14255-8; PMID:7782278; http://dx.doi.org/10.1074/jbc.270.24. 14255
24. Abate A, Oberle S, Schröder H. Lipopolysaccharideinduced expression of cyclooxygenase-2 in mouse macrophages is inhibited by chloromethylketones and a direct inhibitor of NF-kappa B translocation. Prostaglandins Other Lipid Mediat 1998; 56:277-90; PMID:9990673; http://dx.doi.org/10.1016/S0090-6980(98) 00061-6 (Pubitemid 29082545)